文献速递骨软组织肉瘤与黑色素瘤

肿瘤浸润淋巴细胞过继细胞移植治疗转移性肢端雀斑样黑色素瘤

Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma.
PubMed 文献 · J Clin Oncol · 2025-06-13

该研究分析了1999至2018年单中心442例转移性皮肤黑色素瘤患者的ACT-TIL治疗数据,其中30例(7%)为肢端型、412例(93%)为非肢端型。肢端型与非肢端型的客观缓解率分别为43%和40%(P=.87),中位无进展生存期分别为3.5个月和4.1个月(P=.40),中位总生存期分别为13个月和17个月(P=.79)。肢端型黑色素瘤的肿瘤突变负荷和紫外线突变特征评分均低于非肢端型。

要点

  • 肢端型黑色素瘤患者接受ACT-TIL的客观缓解率为43%,非肢端型为40%(P=.87)。
  • 肢端型与非肢端型的中位总生存期分别为13个月和17个月(P=.79)。
  • 肢端型黑色素瘤的肿瘤突变负荷和紫外线突变特征评分低于非肢端型。

核心结论

  • ACT-TIL可在转移性肢端黑色素瘤患者中介导客观缓解,且肢端型患者的结局与非肢端型皮肤黑色素瘤同期治疗患者意外地相当。
  • 需要进一步研究以理解肢端黑色素瘤对ACT-TIL应答的免疫学基础并提高完全缓解率。

研究设计与样本

  • 分析1999至2018年在单中心ACT-TIL临床试验中前瞻性收集的442例转移性皮肤黑色素瘤患者数据。
  • 在不知治疗结局和基因组数据的情况下,根据诊断时临床病理数据回顾性识别肢端亚型患者。
  • 比较肢端型黑色素瘤与非肢端型黑色素瘤同期治疗患者的ACT-TIL治疗结局。

主要发现

  • 442例患者中30例(7%)为肢端型黑色素瘤,412例(93%)为非肢端型黑色素瘤。
  • 肢端型与非肢端型的客观缓解率分别为43%和40%(P=.87),完全缓解率分别为3%和16%(P=.07)。
  • 肢端型与非肢端型的中位无进展生存期分别为3.5个月和4.1个月(P=.40),中位总生存期分别为13个月和17个月(P=.79)。
  • 肢端型黑色素瘤的肿瘤突变负荷和紫外线突变特征评分低于非肢端型黑色素瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Acral lentiginous melanoma is a subtype of cutaneous melanoma arising from palmar, plantar, or subungual skin. These tumors are characterized by aggressive biology, a low tumor mutational burden (TMB), and diminished sensitivity to immune checkpoint blockade. It is unknown whether adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) has efficacy in patients with acral melanoma. METHODS: We analyzed prospectively collected data from 442 patients with metastatic cutaneous melanoma who were treated on clinical trials of ACT-TIL at a single institution between 1999 and 2018. Although blinded to treatment outcome and genomic data, we retrospectively identified patients who had acral subtype on the basis of clinicopathologic data available at the time of diagnosis. We then evaluated the ACT-TIL treatment outcomes of patients with acral melanoma and compared them with contemporaneously treated patients with nonacral melanoma. RESULTS: Out of 442 included patients, 30 (7%) had acral melanoma while 412 (93%) had nonacral melanoma. Cohorts had similar clinical characteristics, protocol enrollment, and treatment-related factors. The objective response rate to ACT-TIL in patients with acral and nonacral melanomas was 43% and 40%, respectively (P = .87), with 3% and 16% having complete responses (CRs; P = .07). Median progression-free survival was 3.5 and 4.1 months (P = .40) and median overall survival was 13 and 17 months (P = .79), respectively. Acral melanomas had lower TMB and ultraviolet mutational signature scores than nonacral melanomas. CONCLUSION: ACT-TIL can mediate objective responses in patients with metastatic acral melanoma, and outcomes in patients with acral disease were unexpectedly comparable with those of contemporaneously treated patients with nonacral cutaneous melanoma. Further research is necessary to understand the immunologic basis of responses to ACT-TIL in acral melanoma and to increase the frequency of CRs.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. McClelland PH, Nah SK, Gustafson AM, et al. Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma. J Clin Oncol. 2025. PMID: 40513039. doi:10.1200/JCO-24-02348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。